AXSOME THERAPEUTICS, INC. Costs and Expenses
AXSOME THERAPEUTICS, INC. (AXSM) reported Costs and Expenses of $268.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-06-30 was $268.02M, a 43.51% increase year-over-year.
- AXSOME THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-03-31 was $254.56M, a 42.65% increase year-over-year.
- AXSOME THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-12-31 was $222.96M, a 16.50% increase year-over-year.
- AXSOME THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-09-30 was $217.10M, a 29.70% increase year-over-year.
- AXSOME THERAPEUTICS, INC. costs and expenses for fiscal 2025 was $805.26M, a 20.86% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. costs and expenses for fiscal 2024 was $666.25M, a 32.61% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. costs and expenses for fiscal 2023 was $502.43M, a 118.60% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. costs and expenses for fiscal 2022 was $229.84M, a 84.30% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $268.02M 10-Q · filed 2026-08-10 | $522.58M 10-Q · filed 2026-08-10 | $745.54M derived: sum of 3 quarters · filed 2026-08-10 | $962.64M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $254.56M 10-Q · filed 2026-05-04 | $477.52M derived: sum of 2 quarters · filed 2026-05-04 | $694.62M derived: sum of 3 quarters · filed 2026-05-04 | $881.37M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $222.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $440.06M derived: sum of 2 quarters · filed 2026-02-23 | $626.81M derived: sum of 3 quarters · filed 2026-08-10 | $805.26M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $217.10M 10-Q · filed 2025-11-03 | $403.86M derived: sum of 2 quarters · filed 2026-08-10 | $582.30M 10-Q · filed 2025-11-03 | $773.68M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $186.76M 10-Q · filed 2026-08-10 | $365.20M 10-Q · filed 2026-08-10 | $556.58M derived: sum of 3 quarters · filed 2026-08-10 | $723.97M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $178.44M 10-Q · filed 2026-05-04 | $369.83M derived: sum of 2 quarters · filed 2026-05-04 | $537.21M derived: sum of 3 quarters · filed 2026-05-04 | $702.43M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $191.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $358.77M derived: sum of 2 quarters · filed 2026-02-23 | $523.98M derived: sum of 3 quarters · filed 2026-02-23 | $666.25M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $167.39M 10-Q · filed 2025-11-03 | $332.60M derived: sum of 2 quarters · filed 2025-11-03 | $474.87M 10-Q · filed 2025-11-03 | $644.68M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $165.21M 10-Q · filed 2025-08-04 | $307.49M 10-Q · filed 2025-08-04 | $477.29M derived: sum of 3 quarters · filed 2026-02-23 | $597.20M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $142.27M 10-Q · filed 2025-05-05 | $312.08M derived: sum of 2 quarters · filed 2026-02-23 | $431.99M derived: sum of 3 quarters · filed 2026-02-23 | $543.75M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $169.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $289.72M derived: sum of 2 quarters · filed 2026-02-23 | $401.48M derived: sum of 3 quarters · filed 2026-02-23 | $502.43M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | $119.91M 10-Q · filed 2024-11-12 | $231.67M derived: sum of 2 quarters · filed 2024-11-12 | $332.62M 10-Q · filed 2024-11-12 | $416.91M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-06-30 | $111.76M 10-Q · filed 2024-08-05 | $212.71M 10-Q · filed 2024-08-05 | $297.00M derived: sum of 3 quarters · filed 2025-02-18 | $356.25M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-03-31 | $100.95M 10-Q · filed 2024-05-06 | $185.24M derived: sum of 2 quarters · filed 2025-02-18 | $244.50M derived: sum of 3 quarters · filed 2025-02-18 | $292.50M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $84.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $143.55M derived: sum of 2 quarters · filed 2025-02-18 | $191.55M derived: sum of 3 quarters · filed 2025-02-18 | $229.84M 10-K · filed 2025-02-18 | $229.84M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $59.26M 10-Q · filed 2023-11-06 | $59.26M 10-Q · filed 2022-11-07 | $107.26M derived: sum of 2 quarters · filed 2023-11-06 | $145.55M 10-Q · filed 2023-11-06 | $145.55M 10-Q · filed 2022-11-07 | $178.16M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-06-30 | $48.00M 10-Q · filed 2023-08-07 | $48.00M 10-Q · filed 2022-08-09 | $86.29M 10-Q · filed 2023-08-07 | $86.29M 10-Q · filed 2022-08-09 | $118.90M derived: sum of 3 quarters · filed 2024-02-23 | $152.31M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-03-31 | $38.29M 10-Q · filed 2023-05-09 | $70.90M derived: sum of 2 quarters · filed 2024-02-23 | $104.30M derived: sum of 3 quarters · filed 2024-02-23 | $135.15M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $66.02M derived: sum of 2 quarters · filed 2024-02-23 | $96.86M derived: sum of 3 quarters · filed 2024-02-23 | $124.71M 10-K · filed 2024-02-23 | $124.71M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $33.41M 10-Q · filed 2022-11-07 | $64.25M derived: sum of 2 quarters · filed 2022-11-07 | $92.10M 10-Q · filed 2022-11-07 | |||||
| 2021-06-30 | $30.85M 10-Q · filed 2022-08-09 | $58.69M 10-Q · filed 2022-08-09 | ||||||
| 2020-12-31 | $99.14M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |